Eli Lilly And Stock Cash Flow From Operations
| LLY Stock | MXN 12,600 120.01 0.96% |
Eli Lilly and fundamentals help investors to digest information that contributes to Eli Lilly's financial success or failures. It also enables traders to predict the movement of Eli Stock. The fundamental analysis module provides a way to measure Eli Lilly's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eli Lilly stock.
Eli |
Eli Lilly and Company Cash Flow From Operations Analysis
Eli Lilly's Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Eli Lilly Cash Flow From Operations | 7.26 B |
Most of Eli Lilly's fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eli Lilly and is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Eli Lilly and has 7.26 B in Cash Flow From Operations. This is much higher than that of the Healthcare sector and 46.5% higher than that of the Drug Manufacturers - Major industry. The cash flow from operations for all Mexico stocks is significantly lower than that of the firm.
Eli Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eli Lilly's direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Eli Lilly could also be used in its relative valuation, which is a method of valuing Eli Lilly by comparing valuation metrics of similar companies.Eli Lilly is currently under evaluation in cash flow from operations category among related companies.
Eli Fundamentals
| Return On Equity | 0.65 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.22 % | |||
| Operating Margin | 0.29 % | |||
| Current Valuation | 6.99 T | |||
| Shares Outstanding | 950.18 M | |||
| Shares Owned By Insiders | 0.15 % | |||
| Shares Owned By Institutions | 85.00 % | |||
| Price To Earning | 333.06 X | |||
| Price To Book | 34.76 X | |||
| Price To Sales | 231.96 X | |||
| Revenue | 28.54 B | |||
| Gross Profit | 21.91 B | |||
| EBITDA | 8.28 B | |||
| Net Income | 6.24 B | |||
| Cash And Equivalents | 2.2 B | |||
| Cash Per Share | 2.39 X | |||
| Total Debt | 15.35 B | |||
| Debt To Equity | 648.20 % | |||
| Current Ratio | 1.12 X | |||
| Book Value Per Share | 11.19 X | |||
| Cash Flow From Operations | 7.26 B | |||
| Earnings Per Share | 123.49 X | |||
| Price To Earnings To Growth | 2.23 X | |||
| Number Of Employees | 47 | |||
| Beta | 0.35 | |||
| Market Capitalization | 6.16 T | |||
| Total Asset | 48.81 B | |||
| Annual Yield | 0.01 % | |||
| Five Year Return | 2.46 % | |||
| Net Asset | 48.81 B | |||
| Last Dividend Paid | 3.92 |
About Eli Lilly Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eli Lilly and's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eli Lilly using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eli Lilly and based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly and. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Complementary Tools for Eli Stock analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |